Chemical structure of phenothiazines and their biological activity

Aftab, 1991, Structure-activity relationships of phenothiazines and related drugs for inhibition of protein kinase C, Mol Pharmacol, 40, 798

Ahmad, 1994, Modulation of P-glycoprotein by protein kinase Cα in a baculovirus expression system, Biochemistry, 33, 10313, 10.1021/bi00200a011

Chambers, 1990, Protein kinase C phosphorylates P-glycoprotein in multidrug resistant human KB carcinoma cells, J Biol Chem, 265, 7679, 10.1016/S0021-9258(19)39168-9

Chambers, 1993, Identification of specific sites in human P-glycoprotein phosphorylated by protein kinase C, J Biol Chem, 268, 4592, 10.1016/S0021-9258(18)53436-0

Chen, 2003, Selective amphipatic nature of chlorpromazine binding to plasma membrane bilayers, Biochim Biophys Acta, 1616, 95, 10.1016/S0005-2736(03)00229-3

Chen, 2002, Separation and migration behavior of structurally related phenothiazines in cyclodextrin-modified capillary zone electrophoresis, J Chromatogr A, 979, 399, 10.1016/S0021-9673(02)01501-7

Cheung, 1983, Permissive role of calcium in the inhibition of T cell mitogenesis by calmodulin antagonists, J Immunol, 131, 2291, 10.4049/jimmunol.131.5.2291

Cheung, 1980, Calmodulin plays a pivotal role in cellular regulation, Science, 207, 19, 10.1126/science.6243188

Cieślik-Boczula, 2009, Interactions of dihydrochloride fluphenazine with DPPC liposomes: ATR-IR and31P NMR studies, J Phys Chem B, 113, 15495, 10.1021/jp904805t

De, 1990, Dopamine antagonists: phenothiazine/thioxanthene sar, 1

Ecker, 1999, The importance of a nitrogen atom in modulators of multidrug resistance, Mol Pharmacol, 56, 791

Ermak, 2001, Calcium and oxidative stress: from cell signaling to cell death, Mol Immunol, 38, 713, 10.1016/S0161-5890(01)00108-0

Ford, 1996, Experimental reversal of P-glycoprotein-mediated multidrug resistance by pharmacological chemosensitisers, Eur J Cancer, 32A, 991, 10.1016/0959-8049(96)00047-0

Ford, 1988, Structural features determining activity of phenothiazines and related drugs for inhibition of cell growth and reversal of multidrug resistance, Mol Pharmacol, 35, 105

Ganapathi, 1991, Relationship between of P glycoprotein and efficacy of trifluoperazine in multidrug-resistant cells, Mol Pharmacol, 39, 1

Hait, 1992, Rational design and pre-clinical pharmacology of drugs for reversing multidrug resistance, Biochem Pharmacol, 43, 103, 10.1016/0006-2952(92)90667-8

Hait, 1985, Inhibition growth of leukemic cells by inhibitors of calmodulin: phenothiazines and melittin, Cancer Chemother Pharmacol, 14, 202, 10.1007/BF00258116

Hait, 1985, Characteristics of the cytotoxic effects of the phenothiazine class of calmodulin antagonists, Biochem Pharmacol, 34, 3973, 10.1016/0006-2952(85)90374-0

Hendrich, 2003, Lipids as a target for drugs modulating multidrug resistance of cancer cells, Curr Drug Targets, 4, 23, 10.2174/1389450033347172

Hendrich, 2003, New phenothiazine-type multidrug resistance modifiers: anti-MDR activity versus membrane perturbing potency, Biochem Biophys Res Commun, 304, 260, 10.1016/S0006-291X(03)00580-1

Hendrich, 2003, Neither lipophilicity nor membrane-perturbing potency of phenothiazine maleates correlate with the ability to inhibit P-glycoprotein transport activity, Mol Membr Biol, 20, 53, 10.1080/0968768031000045815

Jaszczyszyn, 2006

Liu, 1996, Site-directed fluorescence labeling of P-glycoprotein on cysteine residues in the nucleotide binding domains, Biochemistry, 35, 11865, 10.1021/bi960823u

Liu, 2000, Intrinsic fluorescence of the P-glycoprotein multidrug transporter sensitivity of tryptophan residues to binding of drugs and nucleotides, Biochemistry, 39, 14927, 10.1021/bi0018786

Michalak, 2001, Compounds that modulate multidrug resistance in cancer cells, Cell Biol Mol Lett, 6, 362

Michalak, 2002, Lipid membrane perturbation caused by some isoflavones and phenothiazines, and the activity of these compounds as inhibitors of multidrug resistance, Cell Mol Biol Lett, 7, 293

Morak-Młodawska, 2009, New derivatives of phenothiazines with anticancer activities (Polish), Pol Merk Lek, 159, 671

Motohashi, 2006, Cytotoxic potential of phenothiazine, Curr Drug Targets, 7, 1055, 10.2174/138945006778226624

Mozrzymas, 1999, Chlorpromazine inhibits miniature GABAergic currents by reducing the binding and by increasing the unbinding rate of GABAA receptors, J Neurosci, 19, 2474, 10.1523/JNEUROSCI.19-07-02474.1999

Pajeva, 1997, QSAR and molecular modeling of catamphilic drugs able to modulate multidrug resistance in tumors, Quant Struct-Act Relat, 16, 1, 10.1002/qsar.19970160102

Pajeva, 1996, Membrane interactions of some catamphilic drugs and relation to their multidrug-resistance-reversing ability, J Cancer Res Clin Oncol, 122, 27, 10.1007/BF01203070

Peroutka, 1980, Relationship of neuroleptic drug effects at brain dopamine, serotonin, alpha-adrenergic and histamine receptors to clinical potency, Am J Psychiatry, 137, 1518, 10.1176/ajp.137.12.1518

Pluta, 2010, Anticancer activity of newly synthesized azaphenothiazines from NCI’s anticancer screening bank, Pharmacol Rep, 62, 319, 10.1016/S1734-1140(10)70272-3

Ramu, 1992, Reversal of multidrug resistance by phenothiazines and structurally related compounds, Cancer Chemother Pharmacol, 30, 165, 10.1007/BF00686306

Sakai, 1999, Synthesis and properties of some novel anti-calmodulin drugs, Bioorg Med Chem, 7, 1559, 10.1016/S0968-0896(99)00092-9

Schleuning, 1993, Growth inhibition of human leukemic cell lines by the phenothiazine derivate fluphenazine, Anticancer Res, 13, 599

Schotte, 1996, Risperi-done compared with new and reference antipsychotic drugs: In vitro and in vivo receptor binding, Psychopharmacology, 124, 57, 10.1007/BF02245606

Seelig, 1998, A general pattern for substrate recognition by P-glycoprotein, Eur J Biochem, 251, 252, 10.1046/j.1432-1327.1998.2510252.x

Seelig, 1998, How does P-glycoprotein recognize its substrates?, J Clin Pharmacol Ther, 36, 50

Seelig, 2000, Substrate recognition by P-glycoprotein and by the multidrug resistance-associated protein MRP1: a comparison, Int J Clin Pharmacol Ther, 38, 111, 10.5414/CPP38111

Seelig, 1994, A method to determine the ability of drugs to diffuse through the blood-brain barrier, Proc Natl Acad Sci USA, 91, 68, 10.1073/pnas.91.1.68

Seelig, 2000, Structure-activity relationship of P-glycoprotein substrates and modifiers, Eur J Pharm Sci, 12, 31, 10.1016/S0928-0987(00)00177-9

Singh, 2010, A cell-based drug efflux assay for analysis of multidrug resistance in cancer patients, Am J Biomed Sci, 2, 178, 10.5099/aj100200178

Snyder, 1974, Drugs, neurotransmitters, and schizophrenia, Science, 184, 1243, 10.1126/science.184.4143.1243

Szwed, 2010, Moving-window 2D correlation spectroscopy in studies of fluphenazine-DPPC dehydrated film as a function of temperature, J Mol Struct, 974, 192, 10.1016/j.molstruc.2010.03.053

Taheri, 2010, Effect of MDR1 polymorphism on multidrug resistance expression in breast cancer patients, Genet Mol Res, 9, 34, 10.4238/vol9-1gmr669

Tan, 2000, Multidrug resistance transporters and modulation, Curr Opin Oncol, 12, 450, 10.1097/00001622-200009000-00011

Teodori, 2002, The medicinal chemistry of multidrug resistance (MDR) reversing drugs, Farmaco, 57, 385, 10.1016/S0014-827X(02)01229-6

Ueda, 1992, Human P-glycoprotein transports cortisol, aldosterone, and dexamethasone, but not progesterone, J Biol Chem, 267, 24248, 10.1016/S0021-9258(18)35757-0

Weiss, 1982, Interaction of drugs with calmodulin. Biochemical, pharmacological and clinical implications, Biochem Pharmacol, 31, 2217, 10.1016/0006-2952(82)90104-6

Wilson, 1998, Dopamine D2 and D4 receptor ligands: relation to antipsychotic action, Eur J Pharmacol, 351, 273, 10.1016/S0014-2999(98)00312-4

Zamora, 1988, Physical-chemical properties shared by compounds that modulate multidrug resistance in human leukemic cells, Mol Pharmacol, 33, 454

Zorumski, 1988, Non-competitive inhibition of GABA currents by phenothiazines in cultured chick spinal cord and rat hippocampal neurons, Neurosci Lett, 92, 86, 10.1016/0304-3940(88)90747-1